Skip to main content
Premium Trial:

Request an Annual Quote

New Cancer Biomarker Company Formed in UK

NEW YORK (GenomeWeb News) – A new company called Oxford Cancer Biomarkers has been formed to provide oncology consulting services and new cancer biomarkers.

The company, which is headquartered in Oxford and Reading, UK, is developing new biomarkers using CancerNav, a DNA- and protein-based assay technology platform developed by Nick La Thangue, chair of cancer biology at Oxford University, and David Kerr, professor of cancer medicine at the university.

Quintiles is the largest shareholder in Oxford Cancer Biomarkers. La Thangue, Kerr, and the University of Oxford are the other major shareholders.

Oxford Cancer Biomarkers has a strategic relationship with Quintiles Consulting and Quintiles Global Laboratories, which Quintiles said has the "capabilities and expertise to operationalize the consulting and biomarker R&D innovations" from Oxford Cancer Biomarkers for use by global biopharm companies.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.